Knee, Deborah, Hewes, Becker and Brogdon, Jennifer (2016) Rationale for anti-GITR cancer immunotherapy. European journal of cancer, 67 (NA). pp. 1-10. ISSN 09598049

Abstract

Over the past decade, our understanding of cancer immunotherapy has evolved from assessing peripheral responses in the blood to monitoring changes in the tumor microenvironment. Both preclinical and clinical experience has taught us that modulation of the tumor microenvironment has significant implications to generating robust anti-tumor immunity. Clinical benefit has been well documented to correlate with a tumor microenvironment that contains a dense infiltration of CD8+CD45RO+ T effectors and a high ratio of CD8+ T cells to FoxP3+ Tregs. In preclinical tumor models, modulation of the GITR/GITRL axis suggests this pathway may afford the desired biological outcome of inhibiting Treg function while activating CD8+ T effector cells. This review will focus on the scientific rationale and considerations for the therapeutic targeting of GITR for cancer immunotherapy and will discuss possible combination strategies to enhance clinical benefit.

Item Type:	Article
Date Deposited:	19 Sep 2016 00:45
Last Modified:	19 Sep 2016 00:45
URI:	https://oak.novartis.com/id/eprint/29916